4月30日盘后,康宁杰瑞宣布与石药集团合作开发的HER2双抗KN026联合化疗治疗二线及以后得HER2阳性GC(包括GEJ)的II/III期临床(KN026-001研究)在期中分析结果中达到PFS主要终点。KN026-001研究是一项旨在探索KN026联合化疗治疗一线标准治疗失败后HER2阳性晚期不可切除或转移性GC (包括GEJ)患者的疗效,主要终点为经IRC(独立评审委员会)评估的OS和PFS...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.